Regeneron Announces Investor Conference Presentations
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 9:10 a.m. ET and Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 10:40 a.m. ET.
According to the company, sessions are accessible via its Investors & Media page, with replays and transcripts archived on the website for at least 30 days.
Details
News Market Reaction – REGN
On Feb 12, the first trading day after this news, REGN closed 0.60% above the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
- TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday,
March 4, 2026 - Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday,
March 11, 2026
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.